Mitochondrial and Redox Mechanisms of Leflunomide-Induced Hepatotoxicity Following Repeated Exposure

Document Type : Original Article

Authors

1 Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran

2 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 Students Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Leflunomide is a disease-modifying antirheumatic drug used for inflammatory arthritis. However, aminotransferase elevations and cases of drug-induced liver injury have been reported during therapy. Although leflunomide or its active metabolite has shown antioxidant or protective effects in acute and extrahepatic models, whether repeated hepatic exposure produces a redox–mitochondrial injury phenotype remains insufficiently defined. This study investigated the effects of repeated oral leflunomide administration on hepatic injury markers, oxidative stress, and mitochondrial function in male BALB/c mice. Animals received leflunomide at 5, 10, or 20 mg/kg by gavage for 28 days. Plasma ALT, AST, and LDH were measured. Hepatic oxidative status was assessed by reactive oxygen species formation, lipid peroxidation, reduced glutathione content, ferric-reducing antioxidant power, and the activities of superoxide dismutase and catalase. Liver mitochondria were isolated to evaluate dehydrogenase activity, membrane potential, and calcium-triggered swelling. Repeated leflunomide exposure reduced body weight gain at 10 and 20 mg/kg without altering the liver weight index. ALT and AST were increased in treated animals, whereas LDH remained unchanged. Leflunomide also shifted the hepatic redox profile toward oxidative stress, with increased ROS formation and lipid peroxidation, GSH depletion, reduced antioxidant capacity, and lower SOD and CAT activities. These alterations were accompanied by mitochondrial dysfunction, including reduced dehydrogenase activity, loss of mitochondrial membrane potential, and enhanced mitochondrial swelling. These findings indicate that repeated leflunomide exposure induces a hepatic injury phenotype characterized by oxidative stress and mitochondrial impairment. Sustained liver exposure may reveal mitochondrial liabilities not evident in acute or extrahepatic experimental settings.

Highlights

Abdollah Arjmand (Google Scholar)
Hossein Niknahad (Google Scholar)
Reza Heidari (Google Scholar)

Keywords

References

1.    Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. Ther Adv Gastroenterol. 2023;16:17562848231163410. doi: 10.1177/17562848231163410. 
2.    Weber S, Gerbes AL. Challenges and future of drug-induced liver injury research-laboratory tests. Int J Mol Sci. 2022;23(11):6049. doi: 10.3390/ijms23116049. 
3.    Regev A. Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis. 2014;34(2):227-39. doi: 10.1055/s-0034-1375962. 
4.    Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Kirschbaum BJ. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93(3):198-208. 
5.    Jones PB, White DH. Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol. 2010;2:53-71. doi: 10.2147/OARRR.S9448. 
6.    Chan V, Charles BG, Tett SE. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol. 2005;60(3):257-64. doi: 10.1111/j.1365-2125.2005.02415.x. 
7.    van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf. 2004;27(5):345-52. 
8.    Devarbhavi H, Ghabril M, Barnhart H, Patil M, Raj S, Gu J, et al. Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries. Liver Int. 2022;42(6):1323-1329. doi: 10.1111/liv.15189. 
9.    Sevilla-Mantilla C, Ortega L, Agúndez JA, Fernández-Gutiérrez B, Ladero JM, Díaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis. 2004;36(1):82-4. doi: 10.1016/j.dld.2003.06.002. PMID: 14971821.
10.    Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22(4):335-53. doi: 10.1111/j.1472-8206.2008.00608.x. 
11.    Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, et al. Oxidative stress in drug-induced liver injury (DILI): From mechanisms to biomarkers for use in clinical practice. Antioxidants (Basel). 2021;10(3):390. doi: 10.3390/antiox10030390. 
12.    Robichaux DJ, Harata M, Murphy E, Karch J. Mitochondrial permeability transition pore-dependent necrosis. J Mol Cell Cardiol. 2023;174:47-55. doi: 10.1016/j.yjmcc.2022.11.003. 
13.    Nguyen TT, Wei S, Nguyen TH, Jo Y, Zhang Y, Park W, et al. Mitochondria-associated programmed cell death as a therapeutic target for age-related disease. Exp Mol Med. 2023;55(8):1595-1619. doi: 10.1038/s12276-023-01046-5. 
14.    Hurtado-Navarro L, Angosto-Bazarra D, Pelegrín P, Baroja-Mazo A, Cuevas S. NLRP3 inflammasome and pyroptosis in liver pathophysiology: The emerging relevance of Nrf2 inducers. Antioxidants (Basel). 2022;11(5):870. doi: 10.3390/antiox11050870. 
15.    Zhao S, Chen F, Yin Q, Wang D, Han W, Zhang Y. Reactive oxygen species interact with NLRP3 inflammasomes and are involved   in   the inflammation of sepsis: From mechanism to treatment of progression. Front Physiol. 2020;11:571810. doi: 10.3389/fphys.2020.571810. 
16.    Ozturk E, Surucu M, Karaman A, Samdancı E, Fadillioglu E. Protective effect of leflunomide against oxidative intestinal injury in a rodent model of sepsis. J Surg Res. 2014;187(2):610-5. 
17.    Yildiz Y, Kose H, Cecen S, Ergin K, Demir EM, Serter M. Protective effects of leflunomide on intestinal ischemia-reperfusion injury: leflunomide against intestinal ischemia-reperfusion. Dig Dis Sci. 2010;55(2):245-52. doi: 10.1007/s10620-009-0737-0. 
18.    Karaman A, Kirimlioglu H, Tas E, Karadag N, Gülsul C, Fadillioglu E, et al. Effect of leflunomide on liver regeneration after partial hepatectomy in rats. Pediatr Surg Int. 2010;26(2):219-226. doi: 10.1007/s00383-009-2529-1. 
19.    Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol. 1993;14(4):381-94. doi: 10.1007/bf00192310.
20.    Xuan J, Ren Z, Qing T, Couch L, Shi L, Tolleson WH, et al. Mitochondrial dysfunction induced by leflunomide and its active metabolite. Toxicology. 2018;396-397:33-45. doi: 10.1016/j.tox.2018.02.003. 
21.    Elshaer RE, Tawfik MK, Nosseir N, El-Ghaiesh SH, Toraih EA, Elsherbiny NM, et al. Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K/mTOR/NFκB pathway. Life Sci. 2019;235:116824. doi: 10.1016/j.lfs.2019.116824. 
22.    Hesketh EE, Vernon MA, Ding P, Clay S, Borthwick G, Conway B, et al. A murine model of irreversible and reversible unilateral ureteric obstruction. J Vis Exp. 2014;(94):52559. doi: 10.3791/52559. 
23.    Heidari R, Niknahad H. The role and  study of  mitochondrial impairment and oxidative stress in cholestasis. Methods Mol Biol. 2019;1981:117-132. doi: 10.1007/978-1-4939-9420-5_8. 
24.    Heidari R, Ommati MM, Niknahad H. Methods for measuring brain mitochondrial impairment and oxidative stress in hepatic encephalopathy. In: Experimental and Clinical Methods in Hepatic Encephalopathy Research. Springer US New York, NY; 2025:293–313.
25.    Shafiekhani M, Ommati MM, Azarpira N, Heidari R, Salarian AA. Glycine supplementation mitigates lead-induced renal injury in mice. J Exp Pharmacol. 2019;11:15-22. doi: 10.2147/JEP.S190846. 
26.    Heidari R, Rasti M, Shirazi Yeganeh B, Niknahad H, Saeedi A, Najibi A. Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine. Bioimpacts. 2016;6(1):3-8. doi: 10.15171/bi.2016.01. 
27.    Mosedale M, Watkins PB. Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther. 2017;101(4):469-480. doi: 10.1002/cpt.564. 
28.    Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 2009;32(12):1123-34. doi: 10.2165/11316650-000000000-00000. 
29.    Hopkins AM, Wiese MD, Proudman SM, O'Doherty CE, Foster D, Upton RN. Semiphysiologically based pharmacokinetic model of leflunomide disposition  in  rheumatoid  arthritis patients. CPT Pharmacometrics Syst Pharmacol. 2015;4(6):362-71. doi: 10.1002/psp4.46. 
30.    Ma LL, Wu ZT, Wang L, Zhang XF, Wang J, Chen C, et al. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity. Acta Pharmacol Sin. 2016;37(3):415-24. doi: 10.1038/aps.2015.157.
31.    Heidari R, Niknahad H, Jamshidzadeh A, Eghbal MA, Abdoli N. An overview on the proposed mechanisms of antithyroid drugs-induced liver injury. Adv Pharm Bull. 2015;5(1):1-11. doi: 10.5681/apb.2015.001. 
32.    Heidari R, Niknahad H, Jamshidzadeh A, Abdoli N. Factors affecting drug-induced liver injury: antithyroid drugs as instances. Clin Mol Hepatol. 2014;20(3):237-48. doi: 10.3350/cmh.2014.20.3.237. 
33.    Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev. 2012;44(1):88-106. doi: 10.3109/03602532.2011.602688. 
34.    Mihajlovic M, Vinken M. Mitochondria as the target of hepatotoxicity and drug-Induced liver injury: Molecular mechanisms and detection methods. Int J Mol Sci. 2022;23(6):3315. doi: 10.3390/ijms23063315. 
35.    Naeem A, Jahan N, Khan MM, Abbas G, Siddiqui F, Khalid MU, et al. Effect of leflunomide-metal complexes on ROS, TNF, and brain indolamines in comparison with anti-depressants as adjunct therapy inrheumatoid arthritic model. Biomedicines. 2023;11(8):2214. doi: 10.3390/biomedicines11082214. 
36.    Karaman A, Fadillioglu E, Turkmen E, Tas E, Yilmaz Z. Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver. Pediatr Surg Int. 2006;22(5):428-34. 
37.    Kayhan S, Guzel A, Duran L, Tutuncu S, Guzel A, Gunaydın M, et al. Effects of leflunomide on inflamation and fibrosis in bleomycine induced pulmonary fibrosis in wistar albino rats. J Thorac Dis. 2013;5(5):641-9. 
38.    Shrestha AK, Menon RT, Shivanna B. Leflunomide attenuates oxidative stress in fetal human lung endothelial cells via superoxide dismutase 2 and catalase. Biochem Biophys Res Commun. 2018;503(3):2009-2014. 
39.    Ozturk E, Demirbilek S, Begec Z, Surucu M, Fadillioglu E, Kirimlioglu H, et al. Does leflunomide attenuate the sepsis-induced acute lung injury? Pediatr Surg Int. 2008;24(8):899-905. doi: 10.1007/s00383-008-2184-y. 
40.    Latchoumycandane C, Seah QM, Tan RC, Sattabongkot J, Beerheide W, Boelsterli UA. Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes. Toxicol Appl Pharmacol. 2006;217(1):125-33. doi: 10.1016/j.taap.2006.08.001. 
Trends in Pharmaceutical Sciences and Technologies
Volume 12, Issue 1
March 2026
Pages 81-92

Files

Share

How to cite

Statistics